The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next to Merck’s contract pharmacy policy and to AstraZeneca’s contract pharmacy lawsuit.
What Will HRSA do About Merck’s Policy?
In the wake of federal district judges’ recent decisions in drug manufacturers' 340B contract pharmacy lawsuits, we are keeping close tabs on what happens next to Merck’s contract pharmacy policy and to AstraZeneca’s contract pharmacy lawsuit.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
